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ABSTRACT
ID4, a helix loop helix transcriptional regulator has emerged as a tumor suppressor 
in prostate cancer. Epigenetic silencing of ID4 promotes prostate cancer whereas 
ectopic expression in prostate cancer cell lines blocks cancer phenotype. To directly 
investigate the anti-tumor property, full length human recombinant ID4 encapsulated 
in biodegradable Polycaprolactone/Maltodextrin (PCL-MD) nano-carrier was delivered 
to LNCaP cells in which the native ID4 was stably silenced (LNCaP(-)ID4). The cellular 
uptake of ID4 resulted in increased apoptosis, decreased proliferation and colony 
formation. Intratumoral delivery of PCL-MD ID4 into growing LNCaP(-)ID4 tumors in 
SCID mice significantly reduced the tumor volume compared to the tumors treated 
with chemotherapeutic Docetaxel. The study supports the feasibility of using nano-
carrier encapsulated ID4 protein as a therapeutic. Mechanistically, ID4 may assimilate 
multiple regulatory pathways for example epigenetic re-programming, integration 
of multiple AR co-regulators or signaling pathways resulting in tumor suppressor 
activity of ID4.
INTRODUCTION
Inhibitor of differentiation 4(ID4), a helix loop helix 
transcriptional regulator [1] has emerged as a major tumor 
suppressor in prostate cancer (PCa) [2]. EZH2 dependent 
epigenetic silencing of ID4 is observed in majority of 
PCa with increasing grade [3]. Genetic ablation of ID4 
in non-tumorigenic PCa cell lines such as androgen 
sensitive LNCaP cells promotes tumorigenicity and 
castration resistance phenotype both in vitro and in vivo 
[4]. Alternatively over-expression of ID4 in tumorigenic 
DU145 cells that lack native ID4 attenuates their growth 
and promotes androgen receptor expression [5]. Studies 
have demonstrated that genetic ablation of Id4 in mice 
(Id4-/-) leads to attenuated prostate development and 
PIN lesions as early as 6 weeks post-partum which is 
associated with a pro-neoplastic phenotype (Pten-, Id1+, 
pAkt+, Ki67+, Nkx3.1-) [6]. These studies suggest that ID4 
deficiency is a major event in PCa. Thus re-introducing ID4 
in PCa cells could be a potential PCa therapeutic approach.
ID4 promotes p53 [7] and androgen receptor 
(AR) transcriptional activity [4], promotes senescence 
independently of p16 and Rb and induces the expression of 
multiple cyclin dependent kinase inhibitors (CDKNI) [5, 
8]. Lack of the DNA binding domain in ID4 [1] suggests 
that most of its biological activity could be due to protein-
protein interactions. In fact, recent studies have shown that 
ID4 can interact and functionally inhibit the activity of 
bHLH proteins TWIST1 [9] and the ID paralogs ID1, ID2 
and ID3 [10] which are up-regulated in PCa [11, 12].
The intracellular proteins, specifically tumor 
suppressor proteins whose expression is either lost/and or 
mutated (e.g. PTEN, Rb, and p53) have crucial roles in 
either initiation and/or progression of cancer [13]. Thus 
restoring the tumor suppressor activity either through 
genetic, protein delivery (whole proteins, small peptide 
mimetics) and/or epigenetic modifications is considered 
as the hall marks of cancer therapeutics [14, 15].
As “information rich” macromolecules, protein/
peptide drugs offer incredible selectivity, high target 
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specificity, low toxicity and associated unwanted side 
effects. It is therefore not surprising that proteins/peptides 
are the ultimate drugs of choice for treatment of various 
diseases including cancer. In spite of these advantages, 
the use of proteins or peptides to treat cancers is a 
challenging approach due to poor stability and low cellular 
permeability. Consequently, multiple approaches are 
currently being explored to protect the biological activity 
of proteins, aid in intracellular transport and enhance 
target specificity through engineered protein modifications 
and delivery methods (Reviewed in [15, 16]). Success has 
been achieved with proteins/peptide drugs and antibodies 
with some of them in clinical trials [17, 18]. Advances 
in nanotechnology has made it possible to encapsulate 
proteins/peptides to minimize degradation and tissue/
site targeting through appropriate modifications resulting 
in increased uptake and intracellular activity (reviewed 
in [19, 20]). Recent studies have in fact demonstrated 
successful targeted delivery (receptor mediated 
endocytosis) of nano-encapsulated p53 into cancer cells 
resulting in apoptosis [21].
More recently, the use of biodegradable nanocarriers 
(NC) such as PLGA [20] and polycaprolactone (PCL)- 
maltodextrin (MD)[22] has gained significant attention 
to deliver protein intracellularly. The PCL-MD based 
NC are particularly interesting since both are FDA 
approved with minimum cytotoxicity [22, 23]. PCL-MD 
based NC can efficiently deliver large macromolecules 
such as BSA into the PCa cells while maintaining the 
secondary structure [22]. Building upon these preliminary 
observations, we developed the bio-degradable PCL-MD 
NC encapsulating recombinant ID4 (ID4NC). The tumor 
suppressor activity of ID4NC was investigated in vitro 
and in vivo in castration resistant PCa cell line LNCaP in 
which ID4 was knocked down via gene specific shRNA. 
Our results suggest that ID4NC delivered functional ID4 
into the cells in which ID4 was knocked down at the gene 
level, resulting in growth inhibition both in vitro and 
in vivo.
RESULTS
The detailed characterization of PCL-MD 
NC, including internalization mechanism, kinetics, 
biocompatibility with various PCa cells lines and sub-
cellular localization has been reported earlier [22]. In this 
study we focused on investigating the therapeutic potential 
of PCL-MD NC with encapsulated ID4.
ID4 is encapsulated in PCL-MD NCs
Immunoblotting of L(-)ID4 cells demonstrated that 
ID4 was released from the NCs encapsulated with ID4 
(ID4NC) as opposed to blank NCs (Figure 1B). These 
results indicated successful ID4 encapsulation process 
outlined in Figure 1A.
Figure 1: A. Schematic flow chart for the synthesis of PCL-MD NC and subsequent encapsulation of recombinant ID4. The details of the 
process are outlined in materials and methods. B. Western blot analysis of ID4. 500 ng of recombinant ID4 (ID4, positive control) was used 
in an immunoblot analysis to demonstrate that ID4 is released from the nano carriers (ID4NC). No ID4 was detected in the unloaded/blank 
nano carriers (NC). The blot is represented of more than 4 experiments.
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Uptake of nano-carrier encapsulated ID4
The L(-)shNS cells expressed ID4 (Figure 2A and 
2C) whereas L(-)ID4 lacked detectable ID4 protein (Lack 
of red staining in L(-)ID4, Figure 2D and 2F), confirming 
our earlier studies [4].
Incubation of ID4NC with L(-)ID4 cells led to 
increased intracellular levels of ID4. The expression of 
ID4 was observed in both the cytoplasm and nucleus that 
was consistent with the native ID4 expression pattern 
(compare Figure 2G, 2I, 2J, 2L with 2A and 2B). In 
contrast, no ID4 expression was observed in the L(-)ID4 
cells incubated with NC alone (Figure 2M and 2O). In 
another set of experiments, we incubated L(-)ID4 cells 
with ID4 alone. In this setting, no ID4 was observed in 
the L(-)ID4 cells after 1 or 2 hrs of incubation. The ID4 
ICC in these cells was similar to that shown for L(-)ID4 
(Figure 2D and 2F) hence the data is not shown. These 
results confirmed that uptake of ID4 in L(-)ID4 cells is 
dependent on its encapsulation in NC.
ID4NC blocks survival of L(-)ID4 cells
The NCs are biocompatible with normal prostate 
epithelial cells and PCa cell lines [22]. Therefore a 
significant change in the number of apoptotic cells in 
L(-)ID4 with or without NC for at least 24 hrs was 
not expected (Figure 3A). However, in the presence 
of ID4NC for 12 and 24hrs, a significant increase 
in the number of apoptotic cells (12hrs: 39.1±5.2, 
24hrs: 65.66±7.2, P<0.001) as compared to untreated 
(20.48±3.1) or treated with NC alone (13.82±2.3) was 
observed (Figure 3A). An ID4 dependent increase 
in apoptosis was also associated with a concomitant 
decrease in the number of live cells (Figure 3A). These 
results are consistent with our earlier studies showing 
that over-expression of ID4 in DU145 cells promote 
apoptosis [8] whereas silencing of ID4 in LNCaP cells 
attenuates apoptosis [4].
Loss of ID4 in LNCaP cells promotes cell cycle 
by shortening the G1/G0 phase [4]. Restoring ID4 
expression through ID4NC dependent intracellular 
delivery significantly increased G1 arrest in L(-)ID4 
cells (81.7±10.2 and 76.55±5.4% at 12 and 24hrs 
respectively, P<0.001) as compared to untreated 
(63.2±5.3) or treatment with NC alone (57.9±6.1) 
(Figure 3B). An increase in the population of cells 
in subG0 phase, a crude estimation of apoptotic cells 
confirmed increased in apoptosis after ID4NC treatment 
as compared to controls. A significant decrease in the 
fraction of cells in S- (3.2±0.5 and 2.1±0.4: 12 and 
24 hrs respectively) and G2/M phase (0.6±0.08 and 
0.46±0.66: 12 and 24 hrs respectively) further suggested 
that the cells are primarily arrested in the G1 phase 
following treatment with ID4NC.
ID4NC blocks, invasion and anchorage 
independent cell growth
We have shown earlier that knockdown of ID4 in 
LNCaP cells (L(-)ID4) promotes invasion and anchorage 
independent cell growth [4]. Restoring ID4 expression 
in L(-)ID4 cells with ID4NC decreased invasion through 
matrigel by at least 4 fold (p<0.001) as compared to 
L(-)ID4 cells (Figure 4A-4C and 4D). The anchorage 
independent growth of L(-)ID4+NC cells in soft agar 
demonstrated approximately 2 fold (p<0.001) decrease 
in number of colonies as compared to L(-)ID4 and L(-)
ID4+NC cells used as controls (Figure 4E-4G and 4H). 
These results suggested that gain of ID4 attenuates 
invasion and anchorage independent growth, the hallmarks 
of an aggressive cancer, supporting its role as a tumor 
suppressor.
ID4 PCL-MD NCs blocks tumor growth of 
subcutaneous xenografts in vivo
The L(-)ID4 cells are castration resistant and readily 
forms tumors in intact and castrated nude mice [4]. In this 
study, the L(-)ID4 cells were subcutaneously injected into 
the flanks of intact SCID beige male mice to investigate 
the effect of ID4NC on tumor formation. After six weeks 
of initial subcutaneous delivery of cells, the ID4NC were 
injected intratumorally, twice weekly for additional three 
weeks. The experiment was subsequently terminated, 
tumors extracted weighed and volumes measured.
After a latent period of approximately 3 weeks an 
accelerated tumor growth was observed in SCID Beige 
mice injected subcutaneously with L(-)ID4 cells (Figure 
5A). The mean volume of tumors at the end of the six 
weeks and before starting treatments was approximately 
247mm3. Tumor regression was apparent within two 
weeks of the treatment, particularly in xenografts receiving 
ID4NC and ID4NC+ DTX (P<0.01) (Figure 5A). The 
tumor volumes were not different from respective controls 
in mice receiving NC alone (Figure 5A). Following 
excision of the tumors, no significant tumor regression 
was observed in tumors injected with NC alone (weight: 
1.96±0.16gm, volume: 1616.572±367mm3, Figure 5B) 
as compared to tumors in mice receiving no treatment 
(weight: 2.3±0.156gm, volume: 1427±134.7mm3, Figure 
5B, 5C and 5D). These results suggested that NC alone 
had no effect on tumor growth over the treatment period. 
Surprisingly, a highly significant tumor regression 
(weight: 0.294±0.038gm, volume: 130.9±22.4mm3, 
P<0.001) was observed following intratumoral delivery of 
ID4NC in all mice (Figure 5B, 5C and 5D). The total body 
weight between all treatment groups was not significantly 
different (data not shown) and all mice survived the entire 
duration of the experiment suggesting no adverse toxicity 
overall.
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Figure 2: Immuno-cytochemical localization of ID4 in LNCaP cells. The two channels showing blue DAPI (nuclear, B, E, H, 
K, N), red (ID4 protein specific, C, F, I, L, O) staining are shown separately. Both these channels are merged (A, D, G, J and M) to show 
the cellular localization of ID4 in LNCaP cells: transfected with non-specific shRNA (L(-)shNS: A, B and C), stably transfected with ID4 
specific shRNA (L(-)ID4: D, E and F), L(-)ID4 cells treated with ID4 nano carrier for 1hr (L(-)ID4+ID4NC 1hr: G, H and I), L(-)ID4 cells 
treated with ID4 nano carrier for 2hr (L(-)ID4+ID4NC 1hr: J, K and L) and L(-)ID4 cells treated with blank nano carrier for 2hr (L(-)
ID4+NC: M, N and O). The figures are representative of at least three experiments.
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Based on the observations that ID4 promotes 
multiple anti-cancer pathways such as apoptosis and 
androgen receptor activity, we therefore tested the 
hypothesis that a combination of DTX, the first line 
chemotherapy for advanced prostate cancer [24, 25] and 
ID4-NC could have a synergistic effect on the regression 
of tumors than when treated with either DTX or ID4NC 
alone.
Intratumoral delivery of DTX alone also 
significantly reduced the tumor size (weight: 
0.458±0.07gm, volume: 351.7±47.2) as compared to L(-)
ID4 control and blank PCL-MD NC (p>0.001) (Figure 
5B, 5C, 5D). However, the size of DTX treated tumors 
was significantly higher (P<0.01, Figure 5) as compared 
to the ID4NC treated tumors suggesting that ID4NC was 
therapeutically more active in reducing tumor burden as 
compared to DTX alone. The DTX+ ID4NC combination 
significantly (P<0.05) reduced the tumor weight but the 
tumor volumes were similar to ID4NC treated tumors 
(Figure 5B, 5C). Overall, these results suggested that 
ID4NC alone is sufficient to reduce tumor size as 
compared to DTX alone or in combination.
Figure 3: Effect of ID4NC on apoptosis and cell cycle in L(-)ID4 cells. The cells were treated with blank nano carrier (L(-)
ID4+NC) or with ID4 nano carrier (L(-)ID4+ID4NC) for 12 or 24 hrs. Percent L(-)ID4 cells undergoing apoptosis A. Was determined after 
staining the cells with Annexin V–Alexa 488 and PI and with PI alone for cell cycle analysis B. The histogram shows % live and apoptotic 
cells (A) and the percentage of cells in G0-G1, S, and G2-M phases (B). The graphs represent mean±SEM from three replicates and at least 
three independent experiments. (***: P<0.001 by student’s t-test).
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Figure 4: Motility, invasion and anchorage independent growth of L(-)ID4 cells treated with ID4 nano carrier (ID4NC). 
A-C. The invasive capacity of untreated cells (A), or cells treated with blank nano carrier (L(-)ID4+NC) or with ID4 nano carrier (L(-)
ID4+ID4NC) across Matrigel. The number of cells migrated across the Matrigel membrane (Pink, representative image shown) were 
stained (HEMA2 stain set, Fisher) and counted. D. The number of cells migrated across the Matrigel membrane (shown in panels “A-C”) 
were counted and expressed as mean ±SEM (n=3, *P<0.001). E-G. Anchorage independent growth of untreated cells (E), or cells treated 
with blank nano carrier (L(-)ID4+NC, F) or with ID4 nano carrier (L(-)ID4+ID4NC, G) was assessed in a soft agar assay (representative 




The H&E staining of L(-)ID4 xenografts revealed 
a typical morphology of a tumor tissue with large nuclei 
and expansive vascularization [26]. The morphology of 
L(-)ID4 tissue (Supplemental Figure S1A) was similar to 
L(-)ID4+NC (Supplemental Figure S1B) suggesting that 
the blank NC had no observable effect overall. In general 
no pleomorphic nuclei were observed suggesting that the 
cells were clonally derived (from L(-)ID4 cells). No major 
differences were observed between the morphology of 
DTX alone or DTX +NC xenograft tissues.
Tumor apoptosis
The degree of apoptosis in the xenografts was used 
to understand the mechanism of tumor regression in 
response to various treatments. Representative examples 
of apoptosis at the conclusion of the experiments are 
shown in Figure 6A-6F. The increase in the number of 
apoptotic nuclei in ID4NC group as compared to DTX, 
control and NC alone groups is clearly visible in the 
images (compare Figure 6C with 6A, 6B and 6D). The 
apoptotic index was significantly higher in xenografts 
receiving DTX as compared to untreated controls (Figure 
6G, P<0.05). Interestingly, the apoptotic index in response 
of ID4-NC was approximately 3 fold higher as compared 
to DTX treatment (Figure 6G). The combination of DTX 
and ID4NC further increased the number of apoptotic 
cells by 1.5 fold as compared to ID4NC (P=0.04) and 
>5x as compared to DTX alone (P<0.001) (Figure 6G). 
Thus ID4-NC alone or in combination with DTX results 
in a significant increase in apoptosis in the L(-)ID4 cells 
in vivo.
Figure 5: ID4 nano carriers blocks tumor growth in vivo. The L(-)ID4 cells in Matrigel were injected in the right flank of male 
SCID Beige mice. After 6 weeks of growth, the tumors were either left untreated (control, Ctrl, L(-)ID4) or treated (intratumoral injections) 
with blank nano carrier (+NC) or ID4 nano carrier (+ID4NC) with or without DTX twice weekly for 4 weeks. The mice were terminated 
after 10 weeks of initial subcutaneous implantation of cells. A. The volume of the tumors was measured weekly (expressed as mm3, 
mean±SEM, n=6 per group, *: p<0.05) B. The representative xenograft images are shown at the end of the study. C and D. Respective 
weight and volume (mean±SEM, n=6) of the tumors after excision from the mice. The comparisons are between treatments as compared 
to L(-)ID4 cells. Respective within treatment comparisons are shown by lines.(ns: non-significant, *: p<0.05, **: p<0.01, ***: p<0.001).
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Immuno-histochemical analysis
As shown in Figure 7I and 7U, ID4 expression 
was observed by IHC only in L(-)ID4+ ID4NC and L(-)
ID4+ ID4NC+DTX tumors respectively and not in other 
tumors. ID4 localization in tumors receiving ID4NC was 
primarily nuclear although cytoplasmic staining was also 
observed. These results confirmed the successful delivery 
of recombinant ID4 to the tumors and demonstrated the 
specificity of the subsequent results.
Consistent with our earlier studies [4], AR 
expression was detected in all tumors albeit at various 
levels. As reported earlier, a predominantly nuclear 
AR expression was maintained in L(-)ID4 and L(-)
ID4+NC xenografts (Figures 7B and 7F). In contrast, the 
expression of NKX3.1, an androgen induced [27] prostate 
tumor suppressor [28] was essentially undetectable in 
both control groups (Figure 7D and 7H). The expression 
of nuclear AR in ID4NC treated xenografts was more 
diffused and appeared to be lower (Figure 7J) as compared 
to the control groups (Figure 7B and 7F) whereas NKX3.1 
expression used here as a marker of AR activity was the 
highest in xenografts receiving ID4NC (Figure 7L and 
7X).
The AR positive nuclei in DTX treated xenografts 
(Figure 7N, 7R, 7V) was lower than respective controls 
however, NKX3.1 expression though detectable, was still 
significantly lower as compared to ID4NC (Figure 7L). 
Figure 6: Apoptosis in the xenografts as detected by TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end 
labeling assay). The brown color represents apoptotic cells. The sections were counterstained with methyl green hence the green color. 
A. L(-)ID4, B. L(-)ID4+NC, C. L(-)ID4+ID4NC, D. L(-)ID4+ DTX, E. L(-)ID4+NC+ DTX and F. L(-)ID4+ID4NC+ DTX. Representative 
images are shown. G. The apoptotic index (percent apoptotic cells) was calculated by counting the brown nuclei and dividing by total 
number of cells in a field (n=10 field). The data is mean±SEM (*p<0.01, ***p<0.001).
Oncotarget68080www.impactjournals.com/oncotarget
Similar results were obtained when DTX was delivered 
in combination with NC alone (Figure 7R and 7T). In 
contrast, the AR expression appeared more diffused with a 
significant increase in NKX3.1 expression in the presence 
of both DTX and ID4-NC. These results suggested that 
ID4 promotes NKX3.1 expression.
DISCUSSION
The biodegradable PCL and MD are biocompatible 
nano-carriers that demonstrate high cyto-compatibility 
with normal prostate epithelial and PCa cell lines [22]. 
In this study we demonstrate that ID4, a much smaller 
protein (~18kd) as compared to BSA (~66kD) was not 
only encapsulated but was also released in LNCaP cells in 
vitro and in vivo during active tumor growth. Functionally, 
the NC based delivery of recombinant ID4 is biologically 
active in terms of an anti-tumor activity and re-activation 
of tumor suppressor pathways that are relevant in PCa 
such as expression of PCa tumor suppressor NKX3.1 [28, 
29].
Genetic ablation of ID4 in LNCaP cells (L(-)ID4) 
results in constitutively active AR (CRPC) and increased 
tumorigenicity (in vivo and in vitro) [4]. Consequently, re-
constituting ID4 protein expression through ID4NC in L(-)
ID4 reverses these effects suggesting specificity of ID4 
Figure 7: Immuno-histochemical localization (Brown staining) of ID4, AR, Ki67 and NKX3. 1 in L(-)ID4, L(-)ID4+NC, 
L(-)ID4+ID4NC, L(-)ID4+ DTX, L(-)ID4+NC+ DTX and L(-)ID4+ID4NC+ DTX xenografts. Representative images from 3 different 
experiments are shown.
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tumor suppressor pathways such as increase in CDKNIs 
p27 and p21 [4]) and increased apoptosis following ID4NC 
treatment. Collectively, these multiple mechanisms could 
be involved in massive tumor regression in vivo following 
intratumoral NC mediated delivery of recombinant ID4.
Androgen receptor undergoes transition from a 
tumor suppressor in normal prostate to an oncogene in 
PCa [30], which is in part associated with re-programming 
of its transcriptional activity [31]. For example, AR in 
L(-)ID4 cells and prostate epithelial cells from Id4-/- 
mice fails to express NKX3.1 (a homeodomain protein), 
an androgen activated PCa tumor suppressor [27–29] 
[32] [6]. In contrast, NKX3.1 is re-expressed following 
treatment of L(-)ID4 xenografts with ID4NC, which is 
in part associated with a change in AR expression and 
localization. The tumorigenic AR activity during PCa 
progression and specifically in CRPC is dependent on 
multiple factors that include increased stability, post-
translational modifications, interaction with specific co-
regulators, and co-factors and ligand promiscuity. ID4 
may regulate a specific or combination of these pathways 
that may ultimately decide whether AR acts as a tumor 
suppressor or an oncogene. Nevertheless, our results 
provide direct evidence that the constitutive oncogenic AR 
activity in CRPC is reversible, a significant observation. 
The underlying ID4 dependent molecular mechanisms 
could therefore be exploited to develop therapeutic 
strategies to re-activate AR as a tumor suppressor. 
Collectively, our results suggested that ID4NC may 
redirect AR activity from being a tumor promoter to that 
of a tumor suppressor.
Studies have demonstrated that loss of PTEN 
promotes prostate tumorigenesis [33, 34]. The LNCaP 
cells have a deletion of one allele and a mutation of 
the other PTEN allele but surprisingly are still not 
tumorigenic. Thus PTEN loss alone is not an absolute 
requirement for PCa progression towards castration 
resistance. The LNCaP cells acquire castration 
resistance phenotype only when grown for extended 
periods of time under androgen deprived conditions 
as exemplified by the isogenic C81 cell lines [35]. 
Interestingly, the ID4 promoter is also hyper-methylated 
in C81 cells [2]. Based on our results, loss of other 
genes, most notably ID4 together with PTEN appears to 
be a key mechanism involved in acquisition of castration 
resistance phenotype. Reconstitution of ID4 expression 
alone in the PTEN negative background (e.g. L(-)ID4) is 
sufficient to reverse the castration resistance phenotype 
as demonstrated by increased NKX3.1 expression in 
this study. The underlying mechanisms involved in ID4 
dependent regulation of castration resistance are still 
not clear, but appears to be complex since Id4 is also 
required to maintain Pten expression as evident from the 
Id4-/- mice prostates [6].
DTX is the standard first line chemotherapy for 
advanced PCa [24, 25]. Unfortunately, patients treated 
with DTX inevitably develop resistance and relapse 
resulting in a very limited survival advantage [36]. 
Thus understanding the molecular basis of resistance 
and discovering therapeutic strategies/agents that can 
overcome the resistant pathways is urgently needed. In 
an effort to increase survival, combination DTX therapies 
that target androgen receptor pathway, angiogenesis, 
apoptosis and growth factors are currently under clinical 
trials [37]. The L(-)ID4 tumors also appeared at least 
partially resistant to DTX, analogous to DTX resistant, 
androgen insensitive C81 cells [38]. DTX inhibits mitosis 
(blocking tubulin de-polymerization [39]) promotes 
apoptosis (down-regulating bcl-XL and bcl-2 [40]) and 
inhibit AR expression [41, 42] which is consistent with 
our results in L(-)ID4 treated xenografts. Tumor growth 
and IHC studies clearly demonstrates that ID4 promotes 
sensitivity to DTX treatment by significantly promoting 
apoptosis and blocking cell proliferation. These results 
also support earlier studies demonstrating that ID4 
promotes sensitivity to Doxorubicin induced apoptosis 
in DU145 cells [8]. Although the mechanism of action 
of Doxorubicin is different (DNA intercalation) as 
compared to that of DTX, but collectively, these studies 
suggest ID4 expression may promote sensitivity to 
chemotherapeutic drugs, irrespective of their mechanism 
of action.
Mechanistically, how ID4 promotes multiple 
tumor suppressive pathways including sensitivity to 
chemotherapeutic agents is largely unknown. From our 
earlier studies it appears that ID4 dependent acetylation of 
p53 and subsequent activation of p53 dependent pathways 
such as apoptosis, senescence and proliferation could be 
one of the mechanisms [7].
ID4 may also act as inhibitor of inhibitor of DNA 
binding/differentiation protein ID1 through protein-protein 
interactions and subsequent neutralization of its biological 
activity [10]. Multiple studies have shown that increased 
ID1 expression in PCa [12] is associated with castration 
resistance and resistance to chemotherapeutic agents [43–
45]. Since ID4 lacks a DNA binding domain hence most of 
its regulatory actions may involve interactions with other 
proteins. The major observation that needs to be further 
investigated is the ability of ID4 to revert the oncogenic 
AR in PCa back to normal AR activity which appears to 
be that of a tumor suppressor.
The study supports the feasibility of using NC 
encapsulated ID4 protein as a PCa therapeutic. We 
speculate that at the molecular level, ID4 may integrate 
multiple regulatory pathways for example epigenetic re-
programming, integration of multiple AR co-regulators 
or signaling pathways that may ultimately result in tumor 




Human PCa cell line LNCaP was obtained from 
ATCC and maintained at 37 °C and 5% CO2 in RPMI-1640 
supplemented with 10% (v/v) fetal bovine serum (FBS) 
and penicillin/streptomycin. ID4 was stably silenced in 
LNCaP cells using gene specific shRNA (L(-)ID4) as 
described earlier [7]. Non-silencing shRNA transfected 
LNCaP (L(-)shNS) was used as control.
Recombinant ID4
Recombinant ID4 was expressed in E. Coli host 
strain BL21 (DE3) by transforming the pReceiver-B04 
plasmid with GST tagged full length human ID4 
(GeneCopeia Inc) as described previously [10].
Preparation of ID4-loaded nanoparticles
The polycaprolactone (PCL)- maltodextrin (MD) 
encapsulated ID4 (ID4NC) was prepared as previously 
described [22] with modifications. RecombinantID4 
in MD was used as the aqueous phase and a solution 
of PCL in methylene chloride as organic phase (Figure 
1A). A 2% solution of polyvinyl alcohol (PVA) was 
used as a stabilizer. About 5 mg of ID4 protein was used 
for the formulation. Evaporation of the organic phase 
caused coacervation of the polymer and formation of a 
nano-suspension. The nano-suspension was centrifuged 
at 30,000g, washed at least three times with deionized 
water to remove any residual PVA or methylene chloride. 
The nanocarriers were characterized for their size 
and size distribution using Dynamic Light Scattering 
with a Malvern Zetasizer. The particle size, shape and 
morphology was confirmed by Scanning Electron 
Microscopy (Topcon DS-130F Field Emission Scanning 
Electron Microscope at Emory University).
Cell cycle analysis and apoptosis assay
The cells were cultured in RPMI-1640 media 
without serum for 24hrs. Subsequently, the media was 
replaced with RPMI-1640 supplemented with 10% (v/v) 
fetal bovine serum (FBS). At this time, the cells either 
were left untreated (control) or supplemented with blank 
PCL-MD NC (NC) or NC loaded with recombinant ID4 
(ID4NC). The cell cycle distribution was determined after 
24 hours by staining DNA with propidium iodide (PI, 
Calbiochem). Apoptosis was quantitated by staining with 
PI and Alexa Fluor 488 conjugated Annexin V (Molecular 
Probes). The PI or PI+Annexin V cells were analyzed with 
Accuri C6 flow cytometer.
Transwell migration and soft agar colony 
forming assay
Cell migration was performed using Boyden 
chambers according to the manufacturer’s protocol (BD, 
Bedford MA as described previously [4].
For the soft agar colony forming assay, L(-)ID4 
cells along with NC or ID4NC (104 cells/well) were 
suspended in 0.3% Difco Noble agar (Difco, Detroit, MI) 
supplemented with complete RPMI 1640 medium with 
20% FBS. This suspension was layered over 0.8% agar 
base layer in 6 well plates. The plates were incubated at 
37°C with 5% CO2 in a humidified incubator and fresh 
medium was overlaid every 3 days. The colony numbers 
were counted using a microscope after 2-3 weeks of 
incubation.
Immuno -cytochemistry (ICC) and –
histochemistry (IHC)
ICC and IHC protein localization studies on cells 
grown in glass chamber slides or paraffin embedded 5um 
tissue sections respectively was performed as described 
earlier [4, 12]. Non-immune IgG was used as control for 
all immune localization studies and resulted in lack of 
detection of the antigens (data not shown).
Immuno blot analysis
Total cellular proteins were prepared from cultured 
cells using M-PER (Thermo Scientific). Immuno-blot 
analysis using protein specific antibodies were performed 
as described earlier [6] The LAS 3000 imager (Fuji) and 
image quant software was used to capture and quantify 
the images.
Animal studies
All studies were approved by the Clark Atlanta 
University and Mercer University committee for the use 
and care of animals. L(-)ID4 cells (2x106) suspended in 
100 μL of serum-free RPMI 1640 medium containing 
Matrigel (1:1 [v/v], BD Biosciences) were injected 
subcutaneously in 4-week-old male SCID Beige mice 
(Taconic Biosciences, Inc.). After 6 weeks of injection, 
the mice were divided into six different groups. The first 
group received no treatments while the second and the 
third group received intratumoral injections of NC and 
ID4NC, respectively twice a week. The fourth, fifth and 
sixth groups received similar treatments as the above 
three groups along with intraperitoneal injections of the 
Docetaxel (DTX) (5 mg/kg body weight, twice weekly). 
The growth of the tumors was measured each week using 
digital calipers and the volume was calculated. At the 
end of four weeks of treatments, tumors were surgically 
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removed, weighed and the volume was measured. 
Harvested tumors were fixed in 10% buffered formalin. 
The fixed tumors were paraffin embedded, sectioned and 
stained with either hematoxylin and eosin or used for IHC. 
Images were captured using a Zeiss microscope with an 
AxiomCam 4.5 imaging system.
TUNEL assay
Apoptosis in paraffin-embedded sections of the 
xenografts were studied by terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end-labeling (TUNEL) 
assay. Staining was carried out according to the protocol 
provided by the supplier (GeneTex). The number of 
TUNEL positive cells were divided by the total number 
of nuclei in five random fields in order to determine the 
apoptotic index.
Data and statistical analysis
The NIH Image J [46] was used for counting cells 
stained positive for respective antigens in IHC studies [6]. 
Within group Student’s t-test was used for evaluating the 
statistical differences between groups.
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